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See editorial on page 790.
ackground & Aims: Our aim was to establish the
ncidence of symptomatic upper gastrointestinal
lcers, ulcer perforation, ulcer obstruction, or
leeding episodes (PUBs) associated with the use of
elective cyclooxygenase-2 inhibitors at standard
linical doses compared with placebo. We report
ere on the PUB outcomes associated with the use
f rofecoxib 25 mg in a 3-year, multicenter, double-
lind, placebo-controlled trial designed to deter-
ine the effect of rofecoxib on the risk of recurrent
eoplastic polyps of the colon. Methods: A total of
587 patients with a history of colorectal adenomas
nderwent randomization to 25 mg/day of rofecoxib or
o placebo. Investigator-reported PUBs were adjudi-
ated by an external blinded committee. Kaplan–Meier
nd Cox proportional hazards techniques were used to
stimate incidence and relative risks of PUBs in an
ntention-to-treat analysis. Results: Patients assigned
o rofecoxib had a higher incidence of confirmed PUBs
han those randomized to placebo (.88 vs .18 events per
00 patient-years; relative risk, 4.9; 95% confidence in-
erval, 1.98–14.54). The incidence of confirmed compli-
ated PUBs (ulcer perforation, obstruction, or bleeds)
as low, but was numerically higher in the rofecoxib
han in the placebo group (.23 vs .06 events per 100
atient-years; relative risk, 3.8; 95% confidence interval,
72–37.46; P  .14). Rofecoxib increased the incidence of
onfirmed PUBs vs placebo in both low-dose aspirin
sers and nonusers. Conclusions: Among patients
ith a history of colorectal adenomas, the long-term use
f 25 mg/day of rofecoxib was associated with an in-
reased risk of clinically relevant upper gastrointestinal
vents when compared with placebo.onsteroidal anti-inflammatory drugs (NSAIDs) are
used widely for the treatment of pain and inflam-
ation in various rheumatic conditions, but may cause
astrointestinal (GI) ulceration and bleeding, presumably
s a result of inhibition of the cyclooxygenase-1 (COX-
)–mediated production of prostaglandins. Selective in-
ibitors of COX-2 were developed to provide analgesic
nd anti-inflammatory efficacy similar to nonselective
OX inhibitors, but with reduced upper-GI side effects.1
Several placebo-controlled endoscopy studies of osteo-
rthritis or rheumatoid arthritis patients have reported
hat the use of COX-2–selective inhibitors is associated
ith rates of endoscopically determined gastroduodenal
lcers lower than in patients taking nonselective
SAIDs2–5 and either similar2– 4 or slightly higher5 than
bserved in patients taking placebo. Two long-term (12-
o) outcome studies, VIGOR6 (VIOXX Gastrointestinal
utcomes Research) and Therapeutic Arthritis Research
nd Gastrointestinal Event Trial,7 have shown that both
ofecoxib and lumiracoxib were associated with reduced
isks of upper-GI complications and symptomatic gas-
roduodenal ulcers in comparison with nonselective
SAIDs. However, a celecoxib outcomes study, Celecoxib
ong-term Arthritis Safety Study, reported an incidence
f upper-GI complications similar to that observed with
raditional NSAIDs, although when upper-GI complica-
ions were combined with symptomatic peptic ulcers,
elecoxib also was superior to nonselective NSAIDs.8 In a
ore recent short-term (12-wk) trial that compared lower
Abbreviations used in this paper: APPROVe, Adenomatous Polyp
revention On Vioxx; CI, confidence interval; COX, cyclooxygenase; GI,
astrointestinal; PUBs, symptomatic gastroduodenal ulcers, gastrodu-
denal ulcer perforation, obstruction or bleeds; PPI, proton pump
nhibitor; VIGOR, VIOXX Gastrointestinal Outcomes Research.
























































































































February 2007 ROFECOXIB PEPTIC ULCER AND BLEEDING EVENTS 491oses of celecoxib with traditional NSAIDs,9 patients
aking celecoxib had a lower rate of ulcer complications
nd upper gastrointestinal events than those taking tra-
itional NSAIDs.
The relevance of those findings to clinical practice is
nclear because the doses of COX-2 inhibitors in these
rials,6 – 8 but not the doses of the NSAID comparators,
ere higher than those routinely used clinically. Further-
ore, a coherent understanding of the data from the
ndoscopy studies and the outcomes studies has not
een possible because of the lack of a placebo group in
he outcomes studies.6 –9 Also, information on the inci-
ence of GI side effects associated with the use of these
ompounds for other indications in patients without
usculoskeletal diseases (eg, cancer prevention) is lim-
ted.
The Adenomatous Polyp Prevention On Vioxx (APPROVe)
rial was designed to evaluate the hypothesis that adenoma-
ous polyp recurrence would be reduced in patients receiv-
ng rofecoxib, a selective COX-2 inhibitor, for 3 years. In-
estigator-reported symptomatic upper-GI ulcers, ulcer
erforation, obstruction, or bleeds (PUBs) were adjudicated
y an independent committee, and all safety data were
onitored regularly by an external safety monitoring com-
ittee. We report here the upper-GI side effects observed in
he study. The primary efficacy and tolerability data from
his study, and the cardiovascular outcomes, are the subject
f separate reports.10,11
Materials and Methods
The design of the study has been described in
etail elsewhere.10,11 In brief, enrollment occurred from
ebruary 2000 to November 2001 at 108 centers in 29
ountries. Men and women at least 40 years old were
ligible if they had undergone removal of at least 1
istologically confirmed large-bowel adenoma within 12
eeks of study entry. Only patients who were not antic-
pated to need chronic NSAID therapy (including anal-
esic doses of aspirin) during the study and/or patients
ho had not been taking NSAIDs on a chronic basis,
efined as 7 or more total days of each month for the 2
onsecutive months before the screening visit, were en-
olled. Low-dose aspirin for cardiovascular protection
100 mg/day) was allowed, although limited to a max-
mum of 20% of patients at baseline, to minimize the
bility of low-dose aspirin to mask the possible chemo-
reventive effects of rofecoxib. Individuals with a history
f ulcer or dyspepsia were eligible. Patients with uncon-
rolled hypertension (165/95 mm Hg), angina or con-
estive heart failure at rest or with minimal activity,
vidence of occult GI bleeding, or history of small- or
arge-bowel resection were excluded.
Written informed consent was obtained from all pa-
ients enrolled. The study was approved by the institu-
ional review board for each center. The active treatment
eriod was preceded by a 6-week single-blind placebo tun-in to assess patient compliance with study medica-
ion. Patients who took at least 80% of their tablets
uring the placebo run-in were assigned randomly to
eceive either 1 rofecoxib 25-mg tablet or 1 identical-
ppearing placebo tablet daily for 3 years. The computer-
erived randomization was stratified by clinical center
nd low-dose aspirin use, with a blocking factor of 2.
atients, investigators, and study-sponsor personnel in-
olved in study monitoring were blinded to the treatment
llocation schedule. Follow-up evaluation continued un-
il 2 weeks after the last dose of study treatment. There
ere in-person clinic visits at randomization and at
eeks 4, 17, 35, 52, 69, 86, 104, 121, 138, 156, and after
iscontinuation of treatment. At each visit, patients were
sked if they experienced any symptoms or side effects;
ompliance also was monitored. Vital signs were mea-
ured at each clinic visit during the study.
Before the start of the trial, a previously described stan-
ard procedure was instituted for investigators to report
UBs for adjudication.10 The definition of a PUB event in
his trial was identical to that reported previously in GI
utcome studies with rofecoxib,6 and included either the
iagnosis of a gastroduodenal symptomatic ulcer, or the
ccurrence of ulcer perforation, nonmalignant ulcer gastric
utlet obstruction, or upper-GI bleeding. Clinical documen-
ation of investigator-reported candidate PUBs was re-
iewed by a blinded, external adjudication committee. The
ommittee determined whether a suspected PUB was con-
rmed (confirmed PUB), and whether it was a complicated
vent by virtue of the presence of clinically significant up-
er-GI bleeding, obstruction, or perforation, using pre-
efined criteria (confirmed complicated PUB). Confirmed
UBs, the primary GI end point, were included in the
nalysis. Data presented here include events occurring on
tudy drug and up to 14 days after the last dose. An inde-
endent external safety monitoring board met periodically
o review the safety data provided by an unblinded statisti-
ian who was not otherwise involved in the study.
The clinical investigators also recorded more minor GI
dverse events, including episodes of dyspepsia, abdom-
nal pain, and upper-abdominal pain among many oth-
rs; however, these were not adjudicated. Discontinua-
ion because of a GI system adverse experience including
bdominal pain, was prespecified for comparison.
Statistical Analysis
The analysis, performed using SAS software ver-
ion 8.2 (SAS Institute, Cary, NC), included all random-
zed patients who took at least 1 dose of study medica-
ion. We used a Cox proportional hazards model with
reatment as the only factor to compute hazard ratios
relative risks) and 95% confidence intervals (CIs), and
aplan–Meier techniques to estimate cumulative propor-
ions of patients experiencing confirmed PUBs over time.
ubgroup analyses for confirmed PUBs were performed































































492 LANAS ET AL GASTROENTEROLOGY Vol. 132, No. 2roups (ie, interactions). There were no stratification fac-
ors or covariates in the analysis models because the
umber of events was small. Demographic and clinical
ata also were tested one at a time to assess whether the
ariable was a significant risk factor for PUBs in the
ntire population of the study. Interaction assessment
as not reported if data were too sparse (eg, 0 events in
ome of the groups). PUB events were monitored up until
4 days after the last dose of study medication. The last
ate a patient took any study medication was on October
4, 2004. The last reported PUB event occurred on Sep-
ember 29, 2004. All reported PUB events were adjudi-
ated and the last date that cases were adjudicated was on
ecember 9, 2004. The data reported here are those
vailable to the authors as of April 27, 2006.
Results
Demographics and Characteristics of
Participants
A total of 3260 patients were screened for inclu-
ion in the study, 2612 were considered eligible and 2587
ere randomized to rofecoxib 25 mg or placebo; all took
t least one dose of study medication, and therefore all
587 were included in the analysis. The treatment groups
ere similar with regard to measured baseline character-
stics including age, sex, and GI risk factors (Table 1).
At baseline, low-dose aspirin (100 mg/day) was taken
y 16.6% of patients randomized to rofecoxib and 15.7%
f those assigned to placebo. The use of other medica-
ions, including antisecretory agents such as H2-blockers
able 1. Patient Characteristics
Male, n (%)
Mean age, (y)
Ulcer history, n (%)
Alcohol user at baseline, n (%)
Caffeine user at baseline, n (%)
Ex/current tobacco user at baseline, n (%)
Low-dose (100 mg/day) aspirin user at baseline, n (%
Low-dose aspirin user during trial, n (%)a
Any dose aspirin user during trial, n (%)b
Antisecretory drug user at baseline, n (%)c
Antisecretory drug user during trial, n (%)d
Proton pump inhibitor user at baseline, n (%)e
Proton pump inhibitor user during trial, n (%)f
Defined as a patient who took 100 mg/day aspirin for at least
edications after a PUB event.
Defined as a patient who took any dose of aspirin or aspirin-containin
tart any of these medications after a PUB event.
Defined as a patient who took 1 dose of H2-blocker or PPI at base
Defined as a patient who took 1 dose of H2-blocker or PPI while o
Defined as a patient who took 1 dose of PPI before randomization
Defined as a patient who took 1 dose of PPI while on study therapr proton pump inhibitors (PPIs), both at baseline and muring the study, was similar in the 2 groups (Table 1). At
he time the study was terminated because of increased
ardiovascular risk with long-term use of rofecoxib (Sep-
ember 2004), 870 patients in the rofecoxib group and
80 patients in the placebo group had completed the 3
ears of study treatment, with a mean on-drug exposure
ime of 2.30 years in the rofecoxib group and 2.48 years
n the placebo group.
Upper-GI PUBs
A total of 27 patients in the rofecoxib group had a
onfirmed PUB (20 uncomplicated and 7 complicated) dur-
ng 3067 patient-years of follow-up evaluation (.88 events
er 100 patient-years; 95% CI, 0.58–1.28). In the placebo
roup there were 6 patients with PUBs (4 uncomplicated






804 (62.5) 805 (61.9)
59.4 59.4
93 (7.2) 94 (7.2)
773 (60.1) 764 (58.8)
1167 (90.7) 1168 (89.8)
776 (60.3) 774 (59.5)
213 (16.6) 204 (15.7)
233 (18.1) 236 (18.2)
245 (19.0) 245 (18.8)
266 (20.7) 275 (21.2)
454 (35.3) 432 (33.2)
185 (14.4) 205 (15.8)
354 (27.5) 341 (26.2)
of the time while on study therapy and did not start any of these






















































































February 2007 ROFECOXIB PEPTIC ULCER AND BLEEDING EVENTS 493nd 2 complicated) during 3342 patient-years of follow-up
valuation (.18 events per 100 patient-years; 95% CI, .07–.39;
bsolute difference: .70 events per 100 patient-years; 95% CI,
.34–1.06). The relative risk was 4.9 (95% CI, 1.98–14.5)
Figure 1). The risk of both duodenal ulcers and gastric
lcers was increased in the rofecoxib group, although the
igure 2. Types of confirmed PUBs with rofecoxib 25 mg/day and pla-
ebo. The gastric or duodenal ulcer event rate include both symptomatic
ncomplicated ulcers and complicated ulcers. Complicated events (7 in
he rofecoxib group and 2 in the placebo group) were all upper GI bleeding
vents and included 3 cases of gastric ulcer and 1 of duodenal ulcer in the
ofecoxib group; no gastric or duodenal ulcer cases were identified in the 2
ases of upper GI bleeding in the placebo group. Twenty patients in the
efecoxib group had uncomplicated symptomatic ulcers (4 patients had
astric ulcers, 14 had duodenal ulcers, and 2 patients had both gastric and
uodenal ulcers. Four patients in the placebo group had uncomplicated
ymptomatic ulcers (3 patients had gastric ulcers and 1 had a duodenal
lcer). There were 2 rofecoxib patients that had both complicated and
ncomplicated PUBs. They are not counted in the 20 patients with uncom-
licated symptomatic ulcers.
able 2. Summary of Rates and Relative Risks for Confirmed








aspirin user at baseline
No 1074 20 .78 (.47–1.20)
Yes 213 7 1.43 (.57–2.94)
ow-dose aspirin user
during triala
No 1054 18 .71 (.42–1.13)
Yes 233 9 1.66 (.76–3.16)
ny dose aspirin user
during trialb
No 1043 18 .72 (.43–1.14)
Yes 244 9 1.59 (.73–3.01)
Defined as a patient who took 100 mg of aspirin or aspirin-contain
ot start any of these medications after a PUB event.
Defined as a patient who took any dose of aspirin or aspirin-containin
tart any of these medications after a PUB event.ncrease seemed greater for the former (Figure 2). The rates
f confirmed complicated PUBs were .23 (95% CI, .09–.43)
nd .06 (95% CI, .01–.22) events per 100 patient-years in the
ofecoxib and placebo groups, respectively (P  .14) (abso-
ute difference, .17 events per 100 patient-years; 95% CI, -.02
o .35). The corresponding rates of confirmed symptomatic
ncomplicated ulcers were .65 (95% CI, .40–1.01) and .12
95% CI, .03–.31) per 100 patient-years (P  .001) (absolute
ifference, .53 events per 100 patient-years; 95% CI, 0.22–
84).There were no deaths associated with the PUB events.
ne patient who was taking placebo died of disseminated
ntravascular coagulation, renal failure, and hepatic failure
0 days after colonoscopy complicated by colonic perfora-
ion, but this event was not counted as a PUB in the analysis
ecause it was located in the large bowel.
Confirmed PUBs were more than 3 times more frequent
n the rofecoxib treatment group than in the placebo group
oth among those who did not use low-dose aspirin during
he trial (P  .005) and among those who did use aspirin
ither at baseline or during the study (P  .014) (Table 2).
urther subgroup analyses were performed to test whether
here were differences in the relative risk (rofecoxib vs pla-
ebo) of confirmed PUBs according to the presence of po-
ential modifying risk factors such as age, sex, race, caffeine
r alcohol use, and smoking. There were no significant
reatment-by-subgroup interactions except for alcohol use,
hich seemed to increase the PUB risk among rofecoxib
ubjects (Table 3).
In this study, ulcer history was a risk factor for PUBs
elative risk (RR, 3.32; 95% CI, 1.36 – 8.09), but the data
ere too sparse to determine whether ulcer history in-
reased the PUB risk among subjects taking rofecoxib
elative to placebo. Data regarding the use of either
2-receptor antagonists or PPIs and rates of PUBs in our
opulation are reported in Table 3.
s According to Aspirin Use






(95% CI) Relative risk (95% CI)
1096 6 .21 (.08–46) 3.67 (1.42–11.17)
204 0 .00 (.00–73) Undefined
1064 6 .22 (.08–.48) 3.25 (1.24–10.00)
236 0 .00 (.00–.61) Undefined
1055 6 .22 (.08–48) 3.25 (1.24–10.01)
245 0 .00 (.00–58) Undefined
roducts for at least 50% of the time while on study therapy and did




Table 3. Summary of Rates and Relative Risks for Confirmed PUBs According to Different Risk Factors
















65 903 17 .77 (.45–1.23) 914 3 .13 (.03–37) 6.11 (1.77–32.52)
65 384 10 1.16 (.56–2.14) 386 3 .31 (.06–91) 3.75 (.96–21.19)
Sexa .331
Male 804 22 1.13 (.71–1.71) 805 4 .19 (.05–.48) 5.99 (2.03–23.90)
Female 483 5 45 (.15–1.05) 495 2 .16 (.02–.59) 2.74 (.45–28.73)
Racea .082
White 1082 20 77 (.47–1.19) 1086 2 .07 (.01–.26) 10.78 (2.62–95.09)
Other 205 7 1.51 (.61–3.11) 214 4 .74 (.20–1.90) 2.04 (.52–9.48)
Caffeine user .224
No 119 3 1.03 (.21–3.01) 132 2 .56 (.07–2.04) 1.83 (.21–21.87)
Yes 1167 24 87 (.55–1.29) 1168 4 .13 (.04–.34) 6.47 (2.22–25.66)
Alcohol user .028
No 505 7 .59 (.24–1.21) 527 5 .38 (.12–.89) 1.55 (.42–6.19)
Yes 773 20 1.08 (.66–1.67) 764 1 .05 (.00–.28) 21.66 (3.46–897.64)
Current cigarette user .329
No 1007 16 66 (.38–1.07) 1015 5 .19 (.06–.44) 3.45 (1.21–12.05)
Yes 280 11 1.74 (.87–3.11) 285 1 .14 (.00–.78) 12.49 (1.82–537.66)
History of upper-GI ulcersa b
No 1194 20 70 (.43–1.08) 1206 6 .19 (.07–.42) 3.61 (1.40–11.00)
Yes 93 7 3.47 (1.39–7.15) 94 0 .00 (.00–1.55) (Undefined)
Use of H2-RA before PUB event .093
No 1114 22 83 (.52–1.26) 1142 3 .10 (.02–.30) 8.16 (1.60–30.50)
Yes 173 5 1.16 (.38–2.71) 158 3 .73 (.15–2.14) 1.59 (.31–10.24)
Use of PPI before PUB event .832
No 951 19 .85 (.51–1.32) 970 5 20 (.06–.47) 4.23 (1.53–14.49)
Yes 336 8 97 (.42–1.92) 330 1 .12 (.00–.44) 8.24 (1.10–365.71
Regiona b
US 660 10 .64 (.31–1.18) 669 0 .00 (.00–.22) (Undefined)
Non-US 627 17 1.13 (.66–1.81) 631 6 .36 (.13–.78) 3.17 (1.19–9.81)
aThese variables were found to be associated as risk factors for PUBs.















































































































































February 2007 ROFECOXIB PEPTIC ULCER AND BLEEDING EVENTS 495Other GI Adverse Events
Reports of other GI adverse events were collected
uring the trial but these were not adjudicated. Treat-
ent discontinuation because of a gastrointestinal ad-
erse experience occurred in 2.95% (95% CI, 2.03–3.88) of
atients taking rofecoxib and 2.23% (95% CI, 1.43–3.04)
f patients taking placebo (P  .27). Among other spe-
ific side effects commonly associated with NSAID use
uch as dyspepsia, abdominal pain, or upper abdominal
ain,12 the proportion of patients who reported having
ne or more of these side effects was 18.6% in the rofe-
oxib group and 18.5% in the placebo arm.
Discussion
In this randomized, placebo-controlled adenoma
hemoprevention trial, we found that, among patients
ith a history of colorectal adenomas, long-term treat-
ent with standard doses of the COX-2–selective inhib-
tor rofecoxib was associated with an increased risk of
onfirmed PUBs compared with placebo. Our findings
re supported by results from a previous smaller long-
erm trial in elderly patients with mild cognitive impair-
ent that also reported an increase in upper-GI events
or rofecoxib vs placebo.13
It is notable, however, that the absolute rate of PUBs in
atients taking rofecoxib was low in this study, lower
han in the VIGOR trial,6 and much lower than that
scribed to conventional NSAIDs.6 – 8 The reasons for the
ifference in rates found in patients taking rofecoxib in
his study and in the VIGOR trial are not clear, but the 3
ain differences between the 2 studies are the dose (50
g/day in VIGOR vs 25 mg/day in APPROVe), the nature
f the baseline disease (rheumatoid arthritis in VIGOR vs
much healthier population in this study), and the use
f PPIs by some patients in the APPROVe study. Other
otential factors such as naive vs chronic users of
SAIDs, or concomitant low-dose aspirin, might have
ended to increase PUB rates in APPROVe.
In contrast to previous experience in patients taking
onselective NSAIDs, rofecoxib was associated with a
reater increase of duodenal ulcers than of gastric ulcers.
his anatomic pattern of ulcer occurrence is consistent
ith similar findings obtained in previous studies with
ofecoxib, including the VIGOR trial6 and Alzheimer dis-
ase studies (Alise Reicin, personal communication,
arch 2006). Because Helicobacter pylori infection is the
ain factor involved in the pathogenesis of duodenal
lcers and previous analyses have reported that H pylori
nfection is a risk factor for peptic ulcer events in patients
aking rofecoxib,14 it would have been of interest to know
he H pylori status of our patients. Unfortunately, this
as not evaluated systematically in this trial.
The only factor identified that significantly modified the
elationship between rofecoxib use and PUB risk was alco-
ol intake. Patients who used alcohol had a rofecoxib rela-ive risk for developing PUBs that was much higher than
hose who did not drink alcohol. Alcohol has been identi-
ed as a risk factor for upper-GI bleeding in patients taking
spirin and NSAIDs in some observational studies,15,16 but
ther studies including randomized controlled trials did
ot confirm this.14,17 On the other hand, alcohol may pro-
ong the bleeding time after NSAID/aspirin use,18 but there
re no data regarding a possible interaction with coxib use.
urthermore, it must be noted that the definition of alcohol
se in this and other studies15–18 is vague and includes
atients using different types of alcohol and different doses
rom infrequent to heavy use.
Dyspepsia is a frequent side effect of NSAID use.1
oxib use has been associated with a lower frequency of
his side effect when compared with nonselective
SAIDs.12 In this study, the frequency of reported dys-
epsia and/or abdominal pain (including upper-abdom-
nal pain) by the investigators was similar in patients and
ontrols, findings consistent with the better profile
coxibs have a lower incidence of dyspepsia when com-
ared to nonselective NSAIDs) described for coxibs than
or nonselective NSAIDs.
Our study had limitations that should be taken into
ccount when considering the clinical implications and con-
lusions obtained. Although the study procedures, event
djudication, and predefined analysis plan addressed GI
utcomes, the study was not designed primarily for this
nalysis. As a result, we may not have optimally identified
nd categorized all potential GI events that occurred during
he trial. A second important limitation is that patients who
sually take COX-2–selective inhibitors may be older and
ave a higher risk of GI complications than our pa-
ients,12,19 differences that may affect the risk of PUBs and
omplications when taking this class of drugs. Finally, the
tudy did not compare rofecoxib users with patients taking
ther analgesics, for example, acetaminophen. Except for
revention studies, such as the one described here, most
atients would take a COX inhibitor for some painful
ondition (eg, arthritis). The results of the present study
how that the risk of upper-GI toxicity is greater with
OX-2–selective inhibitors than with no therapy (placebo),
ut that the absolute risk is low. Physicians and their pa-
ients should weigh the potential risks and benefits of the
se of this class of drugs.
Appendix
The Steering Committee for the APPROVe trial con-
isted of John A. Baron, MD (Chair), Robert S. Bresalier,
D, Robert S. Sandler, MD, Robert Riddell, MD, Dion
orton, MD, Angel Lanas, MD, Bettina Oxenius MD,*
ames A. Bolognese MStat,* and Kevin Horgan, MD.*
The external safety monitoring board consisted of






























































































































496 LANAS ET AL GASTROENTEROLOGY Vol. 132, No. 2arvin A. Konstam, MD, New England Medical Center;
avid Bjorkman, MD, University of Utah Health Sciences
enter; Richard Logan MD, University of Nottingham
chool of Community Health Sciences; and Hui Quan,
hD,* Merck Research Laboratories.
The APPROVe Trial included the following investiga-
ors: M. Aguilar, Clinica Aguilar Bonilla, San Jose, Costa
ica; P. Angus, Austin & Repatriation Medical Centre,
eidelberg, Australia; N. Arber, Tel Aviv Sourasky Med-
cal Center, Tel Aviv, Israel; J. M. P. Badia, Hospital Clinic
Provincial, Barcelona, Spain; R. D. Baerg, Tacoma Di-
estive Disease Center, Tacoma, Washington; H. Baist-
occhi, Unidad de Aparato Digestivo Julio Dante Baist-
occhi, Cordoba, Argentina; M. L. Barclay, Christchurch
ospital, Christchurch, New Zealand; C. Beglinger, Uni-
ersity of Basel, Basel, Switzerland; G. Bianchi-Porro, Os-
edale Luigi Sacco, Milano, Italy; T. Bolin, Prince of
ales Hospital, Randwick, Australia; R. M. Bostick, Pal-
etto Health South Carolina Cancer Center, Columbia,
outh Carolina; J. Bradbury, University Hospital Bir-
ingham, England; R. S. Bresalier, A. A. Dekovich, T.
en-Menachem, S. K. Batra, Henry Ford Hospital, De-
roit, Michigan; E. Bruun, J. Christiansen, Amtssygehuset
Herlev, Herlev, Denmark; C. Burke, Cleveland Clinic
oundation, Cleveland, Ohio; E. Butruk, Akademia Me-
yczna w Warszawie, Warsaw, Poland; L. Capurso,
zienda Ospedaliera San Filippo, Roma, Italy; J. P. Cello,
an Francisco General Hospital, San Francisco, Califor-
ia; M. Chapman, Good Hope Hospital, Sutton Cold-
eld, England; S. Chaussade, Hospital Cochin Saint-
acques, Paris, France; D. P. Cleland, Montreal General
ospital, Montreal, Canada; G. Costamagna, Universita
attolica del Sacro Cuore, Di Clinica Chirurgica, Rome,
taly; P. Crone, Kobenhavns Amtssygehus i Glostrup,
lostrup, Denmark; E. V. Cutsem, Universitaire Zieken-
uizen KU, Leuven, Belgium; G. R. D’Haens, Imeldaziek-
nhuis, Bon Heiden, Belgium; W. Dekker, J. Ferwerda,
ennemer Gasthuis, Haarlem, Netherlands; E.
ominguez-Munoz, Hospital de Conxo, La Coruna,
pain; D. S. Eskreis, R. E. Tepper, Long Island Clinical
esearch Associates, Great Neck, New York; R. Estela,
ospital Clinico San Borja-Arriaran, Santiago, Chile; M.
ärkkilä, University Central Hospital, Helsinki, Finland;
. M. Fugarolas, J. F. deDios, Hospital Universitario
eina Sofia, Cordoba, Spain; A. Giacosa, Instituto Nazio-
ale Per La Ricerca Sul Cancro, Genova, Italy; M. J.
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